gyki 52466 has been researched along with Cerebrovascular Disorders in 1 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchan, AM | 1 |
| Lesiuk, H | 1 |
| Barnes, KA | 1 |
| Li, H | 1 |
| Huang, ZG | 1 |
| Smith, KE | 1 |
| Xue, D | 1 |
1 other study available for gyki 52466 and Cerebrovascular Disorders
| Article | Year |
|---|---|
AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1993 |